Medplus Health Services Ltd
₹ 894
-0.06%
10 Jun
4:01 p.m.
About
Key Points
- Market Cap ₹ 10,704 Cr.
- Current Price ₹ 894
- High / Low ₹ 1,052 / 603
- Stock P/E 71.2
- Book Value ₹ 145
- Dividend Yield 0.00 %
- ROCE 10.5 %
- ROE 9.05 %
- Face Value ₹ 2.00
Pros
Cons
- Stock is trading at 6.15 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 5.61% over last 3 years.
- Promoters have pledged 59.3% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|
1,368 | 1,733 | 2,011 | 2,131 | 2,273 | 2,871 | 3,069 | 3,779 | 4,558 | 5,625 | 6,136 | |
1,336 | 1,696 | 1,940 | 2,073 | 2,153 | 2,737 | 2,852 | 3,507 | 4,292 | 5,270 | 5,649 | |
Operating Profit | 32 | 37 | 71 | 58 | 120 | 134 | 217 | 273 | 266 | 355 | 487 |
OPM % | 2% | 2% | 4% | 3% | 5% | 5% | 7% | 7% | 6% | 6% | 8% |
4 | 8 | 7 | 8 | 11 | 17 | 21 | 31 | 46 | 40 | 49 | |
Interest | 14 | 17 | 19 | 28 | 50 | 47 | 55 | 66 | 83 | 96 | 103 |
Depreciation | 9 | 10 | 11 | 12 | 59 | 75 | 88 | 119 | 182 | 224 | 250 |
Profit before tax | 14 | 19 | 48 | 26 | 23 | 29 | 95 | 118 | 47 | 73 | 183 |
Tax % | 46% | 52% | 40% | -65% | 48% | 94% | 34% | 20% | -6% | 11% | 18% |
7 | 9 | 29 | 42 | 12 | 2 | 63 | 95 | 50 | 66 | 150 | |
EPS in Rs | 419.34 | 508.71 | 1,620.57 | 2,080.06 | 585.46 | 107.02 | 1,393.11 | 8.03 | 4.17 | 5.48 | 12.56 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 16% |
3 Years: | 18% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | 35% |
5 Years: | 142% |
3 Years: | 18% |
TTM: | 139% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 6% |
1 Year: | 27% |
Return on Equity | |
---|---|
10 Years: | 7% |
5 Years: | 7% |
3 Years: | 6% |
Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.17 | 0.17 | 0.17 | 0.19 | 0.19 | 0.19 | 0.45 | 24 | 24 | 24 | 24 |
Reserves | 141 | 137 | 148 | 303 | 291 | 528 | 730 | 1,394 | 1,467 | 1,554 | 1,717 |
170 | 223 | 204 | 162 | 429 | 477 | 590 | 815 | 900 | 1,010 | 1,120 | |
126 | 149 | 183 | 179 | 239 | 344 | 245 | 361 | 406 | 417 | 500 | |
Total Liabilities | 438 | 509 | 535 | 644 | 959 | 1,349 | 1,566 | 2,594 | 2,797 | 3,005 | 3,360 |
67 | 77 | 81 | 83 | 377 | 419 | 517 | 799 | 1,138 | 1,242 | 1,299 | |
CWIP | 3 | 3 | 2 | 1 | 1 | 5 | 6 | 20 | 25 | 11 | 13 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
368 | 429 | 453 | 560 | 580 | 924 | 1,043 | 1,775 | 1,633 | 1,752 | 2,047 | |
Total Assets | 438 | 509 | 535 | 644 | 959 | 1,349 | 1,566 | 2,594 | 2,797 | 3,005 | 3,360 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|
-19 | -17 | 34 | 32 | 147 | -7 | 3 | 170 | 90 | 144 | 540 | |
-16 | -32 | -15 | -18 | -19 | -28 | -35 | -703 | 429 | -83 | -318 | |
67 | 35 | -29 | -1 | -83 | 90 | -6 | 440 | -170 | -198 | -228 | |
Net Cash Flow | 32 | -15 | -10 | 14 | 45 | 56 | -37 | -93 | 350 | -137 | -5 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Inventory Days | 84 | 82 | 76 | 76 | 78 | 101 | 113 | 112 | 117 | 111 | 106 |
Days Payable | 34 | 29 | 25 | 27 | 31 | 37 | 22 | 30 | 27 | 21 | 24 |
Cash Conversion Cycle | 51 | 53 | 51 | 51 | 48 | 65 | 91 | 82 | 91 | 92 | 83 |
Working Capital Days | 42 | 41 | 39 | 39 | 31 | 45 | 69 | 121 | 66 | 68 | 60 |
ROCE % | 11% | 19% | 13% | 12% | 9% | 13% | 10% | 5% | 7% | 10% |
Documents
Announcements
-
Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And
Disclosure Requirements) Regulations, 2015
6 Jun - Three stores' drug licenses suspended; potential revenue loss ~Rs 2.74 lacs over few days.
-
Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015
5 Jun - Subsidiary's drug license suspended 25 days in Maharashtra; potential Rs 7 lakh revenue loss.
-
Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (LODR) Regulations, 2015
1 Jun - Four drug license suspensions in Telangana stores causing minor revenue loss of ~Rs 2.7 lacs.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual Secretarial Compliance Report filed with minor delays, no major violations or penalties.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
30 May - MedPlus Q4 FY25 earnings: 305 net stores added, 15,096 mn revenue, 5.3% EBITDA margin, private label growth.
Annual reports
Concalls
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
India's Leading Pharmacy Company[1][2]
MedPlus is the 2nd largest pharmacy retailer in India, with 4,552 stores across 12 states and 1 union territory as of Q2 FY25. These stores are strategically distributed to maintain a high presence in metro, tier-one, and tier-two cities.
The stores increased with 108 net new stores added in Q2 FY2025, of which 71 were in Tier-2 and Tier-3 cities[3]